Vivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA

Send us a text

Kirk Huntsman, Chairman and CEO of Vivos Therapeutics joins us on this week’s WTR Small-Cap Spotlight following the company announcement of its first known FDA clearance for a medical device in pediatric obstructive sleep apnea. He discusses what the FDA approval means for the millions of US children with this serious health condition. Kirk talks about how the pediatric market fits into Vivos’ new marketing and distribution strategy, as well as the progress with medical-based affiliations.